Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.
about
A Bayesian model for evaluating influenza antiviral efficacy in household studies with asymptomatic infectionsSensitivity analyses comparing time-to-event outcomes only existing in a subset selected postrandomization and relaxing monotonicityStatistical methods for the analysis of clinical trials data containing many zeros: An application in vaccine development.Principal stratification designs to estimate input data missing due to death.On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials.HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 allelesSemiparametric estimation of the average causal effect of treatment on an outcome measured after a postrandomization event, with missing outcome data.Null but not void: considerations for hypothesis testing.Semiparametric estimation of treatment effects given base-line covariates on an outcome measured after a post-randomization event occursCAUSAL EFFECTS OF TREATMENTS FOR INFORMATIVE MISSING DATA DUE TO PROGRESSION/DEATH.A tutorial on principal stratification-based sensitivity analysis: application to smoking cessation studies.Does Finasteride Affect the Severity of Prostate Cancer? A Causal Sensitivity AnalysisIdentification and estimation of survivor average causal effectsThe potential role of biomarkers in HIV preventive vaccine trialsA simple method for principal strata effects when the outcome has been truncated due to death.Interference and Sensitivity Analysis.Study protocol: The Improving Care of Acute Lung Injury Patients (ICAP) studyNonparametric Bounds and Sensitivity Analysis of Treatment Effects.Sensitivity Analysis and Bounding of Causal Effects With Alternative Identifying Assumptions.Randomization-Based Inference within Principal Strata.Two-part test of vaccine effectAssessing treatment-selection markers using a potential outcomes framework.Designs in partially controlled studies: messages from a review.Comparing competing risk outcomes within principal strata, with application to studies of mother-to-child transmission of HIV.A Bayesian approach to estimating causal vaccine effects on binary post-infection outcomesOverview of vaccine field studies: types of effects and designs.Estimating the efficacy of preexposure prophylaxis for HIV prevention among participants with a threshold level of drug concentration.The Minicommunity Design to Assess Indirect Effects of VaccinationPartially hidden Markov model for time-varying principal stratification in HIV prevention trials.Augmented designs to assess immune response in vaccine trialsASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL.Causal Vaccine Effects on Binary Postinfection Outcomes.Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected PostrandomizationEvaluating a surrogate endpoint at three levels, with application to vaccine development.Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.Blood and seminal plasma HIV-1 RNA levels among HIV-1-infected injecting drug users participating in the AIDSVAX B/E efficacy trial in Bangkok, Thailand.On the estimation of a binary response model in a selected population.Statistical approaches for evaluating surrogate outcomes in clinical trials: A systematic review.Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.THE POTENTIAL FOR BIAS IN PRINCIPAL CAUSAL EFFECT ESTIMATION WHEN TREATMENT RECEIVED DEPENDS ON A KEY COVARIATE
P2860
Q30374811-63B6621F-CAF1-4A47-99FC-31A540F20632Q30501153-64143D49-42A3-4BDA-8C10-9A8F8B7E81BEQ30824920-D6830A95-C95B-4442-AD84-D51BA50D13B5Q31126576-7C738DBC-D8A3-4605-98D2-6FD4BD1615DDQ33247446-BFB07F27-D7C6-4BE5-BFA0-E9A72A302887Q33382373-7196E378-B984-478B-A4B9-65621F0727DCQ33509461-83E3D7CE-057D-4D33-8960-5F2245CF20EFQ33666431-2AF36803-0A56-4255-8A80-5F688081421DQ33724675-073D8B49-8EE9-408B-AA47-BC4825762838Q33819683-2E2E4388-5162-4EFE-B451-B2632D67EC70Q33867125-C8E91C0D-03DF-4F24-BF4C-605268FA9B22Q33894354-3462993F-097E-4609-BB5F-A201F9621664Q34040274-DBF46AD4-5E4E-409A-AC3A-E00CBF4ECDD3Q34059957-0A072F63-2C82-46EE-ABFB-DE80218DFEB4Q34760353-40DE2AA2-0C1A-4DF5-BAF6-4F7BD8CA2FC8Q34990758-2DF7FC5B-E559-45FA-8B71-361BC0F5B726Q34999279-FD5FF3A7-047B-4078-A377-DFECD714AF72Q35049922-78C7B57F-F9D6-484B-9BDF-CD801E6F3EF4Q35148372-118A0257-654B-445C-96A5-D44FD592239DQ35285899-1A409B94-8F55-4BF9-A47C-48A38327C481Q35371198-162B73BA-4742-45E7-B09A-0B08908CB0CDQ36157844-172129EC-C976-4F09-97D1-509E6F54035AQ36264282-40F2116C-5C20-462E-BFAA-F5901A7CF56AQ36389148-B7097B67-C6BC-4AA2-BFE0-4D5BA07840CEQ36469702-8EEC7DDA-7F11-4E56-8444-AAD22EE667B4Q36558364-2FD44B7E-0D4C-4A83-9444-84B829F980F5Q36623253-E5865CA0-4DAA-4AE2-8F5A-E67FEB54E4AFQ36769171-37ABDD7F-B77B-473E-809A-B1FE00ADE290Q36829482-7F9F8296-9856-414A-AA47-06446589C9FBQ36877243-E11EC3AF-6DCD-43D0-8A07-FE45B56F32AFQ37012786-7145EF4C-1DB7-4975-8240-D42DA8C4D449Q37016771-49924AF6-C706-4051-8590-9FFCEA9F5935Q37035713-F7D8A7A9-C96C-4E43-A545-60E2C08A3691Q37107029-DA51C4BA-BF2B-4408-B516-0342FA4072A2Q37194359-A126CEEB-9F17-43E2-B2D2-B809426C0404Q37392510-F1057E14-A3DA-42CB-88F0-ACBC69CE6A09Q38548283-5BB3D547-D9C3-4AB8-9B09-38C8E28197F4Q38590481-4F70592B-DD98-4011-BC55-588F4AE00139Q38796580-682B11AC-5A60-4D02-A01B-CF885AD63236Q40775058-6E716FAD-205E-4C7E-8939-E3A9197C0975
P2860
Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Sensitivity analysis for the a ...... al load in HIV vaccine trials.
@ast
Sensitivity analysis for the a ...... al load in HIV vaccine trials.
@en
type
label
Sensitivity analysis for the a ...... al load in HIV vaccine trials.
@ast
Sensitivity analysis for the a ...... al load in HIV vaccine trials.
@en
prefLabel
Sensitivity analysis for the a ...... al load in HIV vaccine trials.
@ast
Sensitivity analysis for the a ...... al load in HIV vaccine trials.
@en
P2093
P2860
P356
P1433
P1476
Sensitivity analysis for the a ...... al load in HIV vaccine trials.
@en
P2093
Michael G Hudgens
Peter B Gilbert
Ronald J Bosch
P2860
P304
P356
10.1111/1541-0420.00063
P407
P577
2003-09-01T00:00:00Z